Guangxi LiuYao Group Co., Ltd, headquartered in Liuzhou, China, is a comprehensive pharmaceutical company primarily engaged in pharmaceutical wholesale, retail, and manufacturing industries. Founded in 1953 as Liuzhou Pharmaceutical Wholesale Station and restructured into a private enterprise in 2002, it is listed on the Shanghai Stock Exchange (Ticker: 603368.SS). The company offers a broad portfolio of products including various pharmaceuticals, traditional Chinese medicine pieces, traditional Chinese medicine formula granules, medical devices, consumables, and test reagents. It operates a wide-reaching distribution network supplying medical and health institutions, pharmaceutical distribution enterprises, and chain pharmacies, while also serving individual consumers through retail pharmacies. Additional business segments include supply chain value-added services, pharmaceutical Internet services, and terminal health services. Guangxi LiuYao Group serves markets primarily across China and has established a significant presence within its regional pharmaceutical industry.
In recent years, the company has implemented strategic initiatives such as stock repurchases and an employee stock ownership plan aimed at enhancing shareholder value and incentivizing personnel. In 2025, Guangxi LiuYao Group launched a stock option incentive program granting 2.872 million stock options to eligible recipients, representing approximately 0.72% of its total share capital, reflecting a focus on talent retention and corporate governance. The company also engaged in active share repurchases, totaling over 5 million shares with a spending of around RMB 93.55 million, signaling confidence in its business outlook. Additionally, Guangxi LiuYao Group has explored collaborations, including high-level exchanges with industry leaders like Huawei to advance pharmaceutical intelligence capabilities, underscoring a commitment to innovation and digital transformation within the pharmaceutical sector.
Overall, Guangxi LiuYao Group stands as a significant player in China's pharmaceutical distribution and manufacturing industries, combining traditional medicine production with modern healthcare product distribution and emerging digital health services, supported by recent strategic financial and operational initiatives to drive sustainable growth and competitiveness in the evolving healthcare market landscape.